Targeting Bcl-2 for cancer therapy

Apoptosis deficiency is one of the most important features observed in neoplastic diseases. The Bcl-2 family is composed of a subset of proteins that act as decisive apoptosis regulators. Research and clinical studies have both demonstrated that the hyperactivation of Bcl-2-related anti-apoptotic effects correlates with cancer occurrence, progression and prognosis, also having a role in facilitating the radio- and chemoresistance of various malignancies. Therefore, targeting Bcl-2 inactivation has provided some compelling therapeutic advantages by enhancing apoptotic sensitivity or reversing drug resistance. Therefore, this pharmacological route turned into one of the most promising routes for cancer treatment. This review discusses some of the well-defined and emerging roles of Bcl-2 as well as its potential clinical value in cancer therapeutics.

Automated summary

Apoptosis deficiency is a crucial feature in neoplastic diseases, with the Bcl-2 family of proteins playing a decisive role in regulating apoptosis. Studies have shown that hyperactivation of Bcl-2 anti-apoptotic effects is associated with cancer occurrence and resistance to therapy, making targeting Bcl-2 inactivation a promising route for cancer treatment.